ARDD began more than a decade ago as a relatively small meeting in Basel, Switzerland, intended to bring pharmaceutical and academic researchers into closer contact around the emerging science of aging. Its move to Boston reflects the field’s expanding commercial and scientific center of gravity. The 2026 program will cover the full path from fundamental mechanisms of aging to therapeutic discovery, clinical development, regulatory planning, licensing and commercialization. That broad scope is significant because aging is not a single disease with one molecular cause. It is a complex biological process involving genomic instability, altered cellular communication, mitochondrial dysfunction, chronic inflammation, loss of proteostasis, stem-cell exhaustion and changes in tissue regeneration. Turning those mechanisms into medicines requires collaboration among specialists who traditionally worked in separate disciplines.

The meeting’s organizers say the 2026 program will be the broadest in ARDD’s history, with participation from major pharmaceutical companies, biotechnology firms, universities, hospitals, financial institutions, scientific publishers and policy organizations. Alex Zhavoronkov, founder and chief executive officer of Insilico Medicine and a co-chair of ARDD, said the event has evolved into a global platform for dialogue among academia, pharmaceutical companies, startups and investors. He described the concentration of participants as evidence that longevity biotechnology is becoming an increasingly important frontier for drug discovery and healthcare. The significance extends beyond the number of organizations involved: pharmaceutical investment can provide the manufacturing, toxicology, clinical and regulatory infrastructure required to move promising aging interventions from experimental models into human studies.

One of the featured presentations will be delivered by Fiona Marshall, president of Biomedical Research at Novartis, under the title “Reimagining Drug Discovery Through the Lens of Aging Biology.” The program will also include a Pharma Chief Executive Panel featuring Christophe Weber, former chief executive officer of Takeda; Elcin Barker Ergun, chief executive officer of Menarini; Marshall; and Ariel Feldstein, chief scientific officer for Internal Medicine at Pfizer. Their participation highlights a central question confronting the industry: how can pharmaceutical research become more productive while addressing biological processes that influence many diseases at once? Aging biology may offer a way to identify shared disease pathways, but it also raises difficult questions about clinical endpoints, patient selection, long-term safety and how regulators should evaluate therapies intended to preserve function across multiple organ systems.

Additional sessions will feature researchers and executives from Eli Lilly, Astellas, GSK, Daiichi Sankyo, Genentech, AstraZeneca, Novo Nordisk, Roche, Sanofi and Lundbeck, among other companies. Academic and medical scientists will be joined by editors and journalists associated with Nature Biotechnology, Nature Medicine, Nature Aging, TIME, the Financial Times, Forbes Health and Genetic Engineering & Biotechnology News. The presence of scientific media is particularly relevant as longevity research attracts extraordinary public attention, along with skepticism about exaggerated claims. Interventions that alter aging-related pathways must be distinguished from products marketed on the basis of weak evidence. Rigorous randomized clinical trials, validated biomarkers and transparent reporting will be essential if the field is to demonstrate that a treatment improves human health rather than merely changing a laboratory measurement.

Artificial intelligence will occupy a major part of the program. Computational systems are increasingly used to analyze biological datasets, identify disease-associated targets, predict molecular interactions and generate candidate compounds. In generative drug discovery, machine-learning models can search chemical space—the enormous universe of possible drug-like molecules—for structures predicted to bind a selected target or possess desirable pharmacological properties. Insilico Medicine has positioned AI-driven discovery at the center of its own development strategy, but the ARDD sessions will examine the technology in a broader context, including large-scale datasets for future AI systems, computational approaches to neurodegeneration, systems immunology and immune aging, and the potential use of AI in clinical trials. These applications could improve trial design by identifying patient subgroups, forecasting treatment response and monitoring biological changes over time, although algorithmic predictions still require experimental and clinical validation.

Dedicated forums will also examine Longevity Medicine, AI in Drug Discovery, Pet and Animal Longevity, and “Virtual Cell in Time: Virtual Aging Cell.” Virtual-cell research seeks to model how cells change across time and under different biological conditions, potentially allowing scientists to simulate disease processes or predict the effects of interventions before testing them in living systems. Animal longevity research may provide another route to discovery because companion animals experience naturally occurring diseases and aging processes in environments that can sometimes resemble human conditions more closely than laboratory models do. Yet translating results across species remains technically challenging. Differences in metabolism, immune function, lifespan and disease biology mean that an intervention that extends survival in an animal model may not produce the same benefit in people.

The investment and business-development program will bring together representatives of Deerfield, OrbiMed, Oaktree Capital Management, Qiming Venture Partners, UBS, Value Partners Group, Danaher Ventures, Morgan Stanley, LongeVC and other organizations. Their sessions will focus on capital formation, therapeutic partnering, licensing and the financial structures needed to support longevity drug development. Developing medicines that target aging-related biology can require long timelines because researchers may need to demonstrate effects on several diseases or functional outcomes rather than on one narrowly defined condition. Investors and companies must therefore assess not only scientific risk but also regulatory strategy, reimbursement, manufacturing feasibility and the commercial implications of therapies that could be prescribed across large aging populations.

Vadim Gladyshev, executive chair of ARDD and professor of medicine at Harvard Medical School, said the biology of aging has become one of biomedical science’s most promising frontiers, while emphasizing that the major challenge is translating fundamental discoveries into interventions that improve healthspan. Morten Scheibye-Knudsen, ARDD co-chair and professor at the University of Copenhagen, said the meeting’s relocation to Boston places it within one of the world’s strongest biomedical innovation ecosystems and reflects the field’s growing emphasis on medicines rather than theory alone. Their comments point to the defining issue for longevity biotechnology: scientific excitement must eventually be matched by measurable improvements in mobility, cognition, metabolic health, resilience and independence.

Insilico Medicine and Eli Lilly are serving as Tier 1 sponsors, with the McKinsey Health Institute as the sole knowledge partner. Additional support comes from AstraZeneca, AbbVie, Human Longevity, Nestlé, Dior, Maxwell Biosciences, BioAge Labs, Gordian Biotechnology, GlycanAge, LongeVC, AniVC, Tolerance Bio, Tally Health, the Institute for Healthier Living Abu Dhabi, Cambrian Bio, Biocytogen, TruDiagnostic and Cyclarity Therapeutics. Synaro Capital, The Cat Health Company and PranaGen Bioscience are Tier 4 sponsors, while Morgan Stanley, Estée Lauder Companies, the Intrinsic Capacity, Frailty & Sarcopenia Research Conference for Healthy Longevity, and quadraScope are listed as Tier 5 sponsors. Registration is open at www.agingpharma.org. Organizers describe ARDD as the world’s largest meeting dedicated to aging and longevity biotechnology, bringing together scientists, clinicians, companies, investors and policymakers to accelerate the conversion of discoveries in aging biology into practical therapeutic programs.

Subject of Research: Aging biology, longevity biotechnology, artificial intelligence in drug discovery, healthspan therapeutics, clinical development, regulatory strategy, investment and pharmaceutical research.

Article Title: ARDD 2026 to Bring Longevity Science, AI and Drug Development Leaders Together at Harvard

News Publication Date: August 20, 2026

Web References: www.agingpharma.org

References: Insilico Medicine announcement on the ARDD 2026 program; statements from Alex Zhavoronkov, Vadim Gladyshev and Morten Scheibye-Knudsen.

Image Credits: ARDD 2026 Program

Keywords: Aging research, longevity biotechnology, healthspan, artificial intelligence, drug discovery, generative AI, clinical trials, pharmaceutical research, aging biology, ARDD 2026, Harvard University, precision medicine, neurodegeneration, immune aging, longevity medicine.

The announcement arrives as longevity research moves rapidly from a largely academic discipline into one of the most closely watched areas of drug development. Researchers are increasingly investigating whether the biological processes that drive aging can be modified rather than simply accepted as inevitable. These processes include the accumulation of senescent cells, chronic low-grade inflammation, declining mitochondrial function, genomic instability, loss of stem-cell activity and changes in cellular communication. Together, they contribute to frailty, metabolic disease, neurodegeneration, cardiovascular disorders and other conditions that rise sharply with age.

ARDD 2026 is expected to focus on how discoveries in geroscience can be converted into medicines that improve healthspan, the period of life spent in relatively good health. The field differs from traditional disease-by-disease drug development because it examines shared biological mechanisms that may influence multiple age-related conditions simultaneously. Scientists are developing biomarkers, animal models, clinical endpoints and computational tools to determine whether an intervention is genuinely altering the aging process or merely treating one consequence of it.

“The biology of aging has become one of the most promising frontiers in biomedical science,” said Vadim Gladyshev, executive chair of ARDD and professor of medicine at Harvard University. He emphasized that the central challenge is translating fundamental discoveries into interventions that improve healthspan, a task that will require collaboration across disciplines and sectors. Such collaboration is increasingly important as researchers combine molecular biology with clinical medicine, artificial intelligence, systems biology, data science and pharmaceutical development.

The meeting will also reflect the growing commercial scale of longevity biotechnology. Organized by Insilico Medicine, ARDD 2026 is anchored by Tier 1 sponsors Insilico Medicine and Eli Lilly, with the McKinsey Health Institute serving as the sole knowledge partner. The conference’s sponsor network includes major pharmaceutical companies, biotechnology firms, diagnostics companies, research organizations, investors and consumer-health businesses. Participating organizations include AbbVie, AstraZeneca, BioAge Labs, Biocytogen, Cambrian Bio, Cyclarity Therapeutics, GlycanAge, Gordian Biotechnology, Human Longevity, Tally Health and TruDiagnostic, among others.

The involvement of pharmaceutical companies is significant because many promising aging interventions remain at the stage of laboratory validation or early clinical testing. Potential approaches include drugs that selectively remove senescent cells, therapies that regulate nutrient-sensing pathways, treatments designed to restore mitochondrial performance and interventions aimed at preserving muscle, immune function or cognitive capacity. Translating these concepts into approved medicines requires evidence that the therapies are safe, produce measurable biological effects and deliver meaningful benefits for patients.

Morten Scheibye-Knudsen, co-chair of ARDD and associate professor at the University of Copenhagen, said the conference’s move to Boston represents a new chapter for the meeting. Boston is one of the world’s leading biomedical innovation hubs, with a dense concentration of universities, hospitals, biotechnology companies and pharmaceutical research centers. According to Scheibye-Knudsen, ARDD 2026 will place particular emphasis on translating scientific discoveries into medicines as the field matures.

The event is designed to connect academic laboratories with companies capable of advancing discoveries through preclinical development, clinical trials and regulatory review. Alex Zhavoronkov, Ph.D., co-chair of ARDD and chief executive officer of Insilico Medicine, described the meeting as a platform for dialogue among academia, pharmaceutical companies, startups and investors. He said the momentum behind the Boston meeting reflects the expanding role of longevity biotechnology in modern drug discovery and health economics.

A central scientific challenge for the field is defining what success should look like. Chronological age alone is a poor measure of biological health, and researchers are therefore studying molecular signatures that may provide more precise assessments of aging. These include DNA methylation patterns, inflammatory markers, immune-cell profiles, protein changes and measurements of physical resilience. Reliable biomarkers could help clinical investigators identify participants most likely to benefit from treatment and determine whether a therapy is changing aging-related biology before long-term health outcomes become visible.

ARDD 2026 will take place against this rapidly changing scientific and financial backdrop. The organizers describe the meeting as the world’s largest conference dedicated to aging and longevity biotechnology, now entering its 13th year. Its broader objective is to accelerate the movement of discoveries from the biology of aging into practical research and development programs. The Nordic Aging Society, a nonprofit scientific organization focused on aging research and collaboration across the Nordic region and beyond, is supporting the event. Further information and interview requests are available through ardd@pharma.ai, while details about the meeting are provided at agingpharma.org.

Subject of Research: Aging biology, longevity biotechnology, geroscience, healthspan extension, and the development of therapies for age-related diseases.

Article Title: Eli Lilly Aging Research Executive to Speak at ARDD 2026 as Longevity Science Enters Drug Development Mainstream

News Publication Date: August 7, 2026

Web References: https://agingpharma.org

Image Credits: ARDD 2026

Keywords: aging research, longevity science, geroscience, healthspan, drug discovery, Eli Lilly, Insilico Medicine, ARDD 2026, senescent cells, biomarkers, biotechnology, pharmaceutical research, Harvard University, healthy aging